Phase II study of everolimus (RAD001) in previously treated small cell lung cancer
A Tarhini, A Kotsakis, W Gooding, Y Shuai, D Petro… - Clinical Cancer …, 2010 - AACR
Purpose: Mammalian target of rapamycin (mTOR) is a promising target in small cell lung
cancer (SCLC). We designed a phase II study of everolimus, an mTOR inhibitor, in …
cancer (SCLC). We designed a phase II study of everolimus, an mTOR inhibitor, in …
Phase II Study of Everolimus (RAD001) in Previously Treated Small Cell Lung Cancer
A Tarhini, A Kotsakis, W Gooding, Y Shuai… - Clinical Cancer …, 2010 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Purpose: Mammalian target of rapamycin
(mTOR) is a promising target in small cell lung cancer (SCLC). We designed a phase II study …
(mTOR) is a promising target in small cell lung cancer (SCLC). We designed a phase II study …
[PDF][PDF] Phase II Study of Everolimus (RAD001) in Previously Treated Small Cell Lung Cancer
A Tarhini, A Kotsakis, W Gooding, Y Shuai… - Clin Cancer …, 2010 - researchgate.net
Purpose: Mammalian target of rapamycin (mTOR) is a promising target in small cell lung
cancer (SCLC). We designed a phase II study of everolimus, an mTOR inhibitor, in …
cancer (SCLC). We designed a phase II study of everolimus, an mTOR inhibitor, in …
[引用][C] Phase II Study of Everolimus (RAD001) in Previously Treated Small Cell Lung Cancer
A TARHINI, A KOTSAKIS, W GOODING… - Clinical cancer …, 2010 - pascal-francis.inist.fr
Phase II Study of Everolimus (RAD001) in Previously Treated Small Cell Lung Cancer CNRS
Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple search …
Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple search …
Phase II study of everolimus (RAD001) in previously treated small cell lung cancer.
A Tarhini, A Kotsakis, W Gooding, Y Shuai… - … Cancer Research: an …, 2010 - europepmc.org
Phase II study of everolimus (RAD001) in previously treated small cell lung cancer. - Abstract -
Europe PMC Sign in | Create an account https://orcid.org Europe PMC Menu About Tools …
Europe PMC Sign in | Create an account https://orcid.org Europe PMC Menu About Tools …
Phase II study of everolimus (RAD001) in previously treated small cell lung cancer
A Tarhini, A Kotsakis, W Gooding, Y Shuai… - Clinical Cancer …, 2010 - pure.psu.edu
Purpose: Mammalian target of rapamycin (mTOR) is a promising target in small cell lung
cancer (SCLC). We designed a phase II study of everolimus, an mTOR inhibitor, in …
cancer (SCLC). We designed a phase II study of everolimus, an mTOR inhibitor, in …
Phase II study of everolimus (RAD001) in previously treated small cell lung cancer
A Tarhini, A Kotsakis, W Gooding… - … : an official journal …, 2010 - pubmed.ncbi.nlm.nih.gov
Purpose Mammalian target of rapamycin (mTOR) is a promising target in small cell lung
cancer (SCLC). We designed a phase II study of everolimus, an mTOR inhibitor, in …
cancer (SCLC). We designed a phase II study of everolimus, an mTOR inhibitor, in …